Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just 7% upside for the stock vs. double that for the rest of the pharmaceutical group (see Eli Lilly upgrade). "We see JNJ as lacking transformational pipeline opportunities." Shares -1.2% premarket.
Are you Bullish or Bearish on ?
Sentiment on ()
Thanks for sharing your thoughts.